Background: Hidradenitis suppurativa (HS) is an inflammatory skin condition that is associated with a prolonged diagnostic delay of approximately 7-10 years. The diagnostic delay can be attributed to various factors, including low awareness of diagnostic criteria among nondermatological healthcare professionals often leading to misdiagnosis. Screening questionnaires have been proposed for the diagnosis of HS. One such questionnaire has been validated and used in the Global Hidradenitis Suppurativa Atlas (GHiSA) Global Prevalence Study (GPS).
Objectives: To evaluate and provide a summary of the diagnostic accuracy measures (pooled sensitivity and specificity) of the screening questionnaire employed in the GHiSA GPS.
Methods: All studies that adhered to the methodology specified by the GHiSA and provided diagnostic accuracy data were eligible for inclusion. Data on geographical location and diagnostic accuracy parameters (true positive, false positive, true negative and false negative) were extracted from the included studies and entered in duplicate into Microsoft Excel independently by two authors. The quality of the studies was assessed using the quality assessment of diagnostic accuracy studies (QUADAS-2) tool.
Results: Data from 25 studies carried out in 23 countries were included in the pooled analysis. The QUADAS-2 assessment revealed a high risk of bias in the domains 'reference standard' and 'patient flow'. For the applicability of the studies, there were concerns about 'patient selection'. Substantial variations in sensitivity (0.43-1.00) and specificity (0.15-1.00) values were observed globally. A bivariate random effects model showed a pooled sensitivity of 0.88 [95% confidence interval (CI) 0.80-0.94] and a pooled specificity of 0.86 (95% CI 0.78-0.91). The summary receiver operating curve revealed a clustering of studies in the upper left corner, indicating a sensitivity and specificity close to 1. The area under the curve was 0.93, suggesting excellent accuracy.
Conclusions: Despite substantial variations in diagnostic estimates around the world, the pooled analysis indicated that the accuracy of the GHiSA screening questionnaire was excellent. The screening questionnaire may prove useful for triage, ensuring that only individuals fitting the criteria for HS see specialized dermatological care.
Hidradenitis suppurativa is a long-lasting and painful skin condition. It is often called ‘HS’ for short. HS can have negative effects on a person’s quality of life. It often takes between 7 and 10 years to diagnose the condition. This may be because some doctors are not aware of the symptoms, or because an incorrect diagnosis is made before the right one. To try to solve this problem, a questionnaire has been created to help doctors diagnose HS. This questionnaire has been used in studies carried out by an organization called the Global Hidradenitis Suppurativa Atlas (or ‘GHiSA’ for short). This international study examined how accurate the questionnaire was in helping to diagnose HS. The researchers looked at data from 25 studies that followed methods recommended by GHiSA. The studies came from 23 different countries and data from the studies was combined. The data was also analysed by country. The researchers found that the questionnaire was very effective. Using the questionnaire helped doctors correctly identify 88% of people who did have HS. They also correctly identified 86% of people who did not have the condition. The researchers found that the accuracy of diagnosis was different in different countries. Using the questionnaire could help doctors diagnose and assess people with HS. This could reduce delays in diagnosing the condition and lead to better outcomes for people.
© The Author(s) 2026. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.